Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 04:01:43 2024-07-11 pm EDT Pre-market 07:35:48 pm
28.66 USD +1.09% Intraday chart for Pfizer, Inc. 28.82 +0.54%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup DJ
Sector Update: Health Care Stocks Rise Late Afternoon MT
PFIZER INC : Jefferies keeps its Buy rating ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
Top Midday Stories: Bain Capital to Acquire Envestnet; Delta, Pepsi Report Q2 Earnings; Pfizer Advances Development of Weight-Loss Pill; DOE Pledges $1.7 Billion for EV MT
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Sector Update: Health Care MT
CureVac Notes New Court Trial Timeline for Patent Cases Against Pfizer, BioNTech MT
Pfizer: advances in anti-obesity pill danuglipron CF
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech MT
Exchange-Traded Funds, Equity Futures Edge Lower Pre-Bell Ahead of Key Inflation Data MT
Pfizer to Advance Development of Modified-Release Formulation of Danuglipron MT
Futures edge lower ahead of inflation test; Delta Airlines falls RE
Pfizer Picks Once-Daily Obesity Pill Version for Further Study DJ
Pfizer moves forward with once-daily weight loss drug RE
Pfizer: collaboration agreement with Evotec in France CF
Barclays Adjusts Pfizer's Price Target to $30 From $28 MT
Sector Update: Health Care Stocks Steady Premarket Wednesday MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases MT
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, infectious Diseases MT
Evotec with new recovery attempt - cooperation with Pfizer DP
PFIZER INC : JP Morgan gives a Neutral rating ZD
Evotec and Pfizer Collaborate to Advance Drug Discovery in France CI
Pfizer: succession open for scientific director CF
Pfizer Begins External Search for Chief Scientific Officer MT
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
28.66 USD
Average target price
32.01 USD
Spread / Average Target
+11.68%
Consensus